What is the main purpose of this acquisition for Amgen?

The primary purpose of this acquisition is to bolster Amgen's pipeline, particularly in the areas of inflammation and nephrology. ChemoCentryx's lead drug candidate, Tavneos (avacopan), is a key asset that is expected to complement Amgen's existing portfolio and strategic focus.

What is the financial consideration for ChemoCentryx shareholders?

ChemoCentryx shareholders will receive $52.00 in cash for each share of common stock they own. Equity awards will also be converted into the right to receive the merger consideration, with unvested awards vesting upon closing.

What are the key conditions for the merger to be completed?

The consummation of the merger is subject to several customary closing conditions. These include the adoption of the merger agreement by ChemoCentryx stockholders, the absence of any legal impediments, and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Both parties also need to meet certain accuracy of representations, absence of material adverse effects, and covenant compliance conditions.

Are there any termination fees associated with this agreement?

Yes, ChemoCentryx may be required to pay Amgen a termination fee of approximately $119 million under specific circumstances. These include if ChemoCentryx terminates the agreement to accept a superior proposal, if Amgen terminates due to a change in ChemoCentryx's board recommendation, or if ChemoCentryx materially breaches its non-solicitation obligations. The fee may also apply if an acquisition proposal is consummated within 12 months after termination under certain conditions.

AMGN 8-K: Material Agreements & Regulation FD

Summary

Amgen Inc. (AMGN) has announced a definitive agreement to acquire ChemoCentryx, Inc. (CCYX) for $52.00 per share in cash, representing a total transaction value of approximately $3.7 billion. This strategic move is aimed at enhancing Amgen's pipeline, particularly in inflammation and nephrology, through ChemoCentryx's lead drug candidate, Tavneos (avacopan). The acquisition is structured as a merger where ChemoCentryx will become a wholly-owned subsidiary of Amgen. The transaction is subject to customary closing conditions, including regulatory approvals (such as HSR Act clearance) and the approval of ChemoCentryx stockholders. Both companies have agreed to use their best efforts to complete the transaction, with provisions for termination fees under specific circumstances, including if ChemoCentryx accepts a superior proposal or if its board changes its recommendation. The deal is expected to close in the fourth quarter of 2022.

Key Highlights

1Amgen to acquire ChemoCentryx for $52.00 per share in cash.
2Transaction valued at approximately $3.7 billion.
3Acquisition expected to strengthen Amgen's inflammation and nephrology portfolio, notably with Tavneos (avacopan).
4Merger agreement entered into on August 3, 2022.
5Closing conditions include ChemoCentryx stockholder approval and antitrust clearance (HSR Act).
6Termination fee of approximately $119 million payable by ChemoCentryx under certain conditions.
7Expected closing in the fourth quarter of 2022.

AMGEN INC 8-K Report, Material Agreement (Aug 4, 2022)

Summary

Key Highlights

Frequently Asked Questions